Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

161. Design and construction of a DNA origami drug delivery system based on MPT64 antibody aptamer for tuberculosis treatment Full Text available with Trip Pro

Design and construction of a DNA origami drug delivery system based on MPT64 antibody aptamer for tuberculosis treatment With all of the developments on infectious diseases, tuberculosis (TB) remains a cause of death among people. One of the most promising assembly techniques in nano-technology is "scaffolded DNA origami" to design and construct a nano-scale drug delivery system. Because of the global health problems of tuberculosis, the development of potent new anti-tuberculosis drug delivery (...) system without cross-resistance with known anti-mycobacterial agents is urgently needed. The aim of this study was to design a nano-scale drug delivery system for TB treatment using the DNA origami method.In this study, we presented an experimental research on a DNA drug delivery system for treating Tuberculosis. TEM images were visualized with an FEI Tecnai T12 BioTWIN at 120 kV. The model was designed by caDNAno software and computational prediction of the 3D solution shape and its flexibility

2016 Electronic physician

162. Systematic Survey of Serine Hydrolase Activity in Mycobacterium tuberculosis Defines Changes Associated with Persistence Full Text available with Trip Pro

Systematic Survey of Serine Hydrolase Activity in Mycobacterium tuberculosis Defines Changes Associated with Persistence The transition from replication to non-replication underlies much of Mycobacterium tuberculosis (Mtb) pathogenesis, as non- or slowly replicating Mtb are responsible for persistence and poor treatment outcomes. Therapeutic targeting of non-replicating populations is a priority for tuberculosis treatment, but few drug targets in non-replicating Mtb are currently known. Here

2016 Cell chemical biology

163. Tuberculosis

Tuberculosis T T uberculosis uberculosis NICE guideline Published: 13 January 2016 nice.org.uk/guidance/ng33 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Tuberculosis (NG33) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 178Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Preventing TB 5 1.2 Latent TB 15 1.3 Active TB 24 1.4 Drug resistant TB 40 1.5 Infection control 42 1.6 Case finding 47 1.7

2016 National Institute for Health and Clinical Excellence - Clinical Guidelines

164. Clinical analysis of retroperitoneoscopic nephroureterectomy for renal tuberculosis Full Text available with Trip Pro

Clinical analysis of retroperitoneoscopic nephroureterectomy for renal tuberculosis To explore the feasibility and safety of retroperitoneoscopic nephroureterectomy for kidney tuberculosis.Forty-eight retroperitoneoscopic nephroureterectomies and thirty-five nephroureterectomies for kidney tuberculosis procedures were performed from June 2008 to December 2014. The patients consisted of 53 males and 30 females with a mean age of 36 years (range: 26-51 years). The patients' data were reviewed (...) , and infection at the incision site was observed in two patients, there were no obvious difference between the two surgical methods (P > 0.05). Seventy-five patients were followed up, and the average follow-up time was 12.5 months (range: 6-20 months). All the patients recovered without any lesions remaining.The results of this study indicate that retroperitoneoscopic nephroureterectomy is a feasible, safe, effective, and less invasive treatment modality for treating renal tuberculosis.

2016 Chronic diseases and translational medicine

165. Smoking cessation interventions for pulmonary tuberculosis treatment outcomes. (Abstract)

Smoking cessation interventions for pulmonary tuberculosis treatment outcomes. Active smoking increases the risk of tuberculosis (TB) infection 2 to 2.5 times and is significantly associated with recurrent TB and TB mortality. Observational studies have shown associations between smoking and poor TB treatment outcomes such as increased loss to follow-up rate, severity of disease, drug resistance and slow smear conversion. Since most smoking-related immunologic abnormalities are reversible

2016 Cochrane

166. Tuberculosis Diagnosis Delaying Treatment of Cancer: Experience From a New Oncology Unit in Blantyre, Malawi Full Text available with Trip Pro

Tuberculosis Diagnosis Delaying Treatment of Cancer: Experience From a New Oncology Unit in Blantyre, Malawi Malawi is a low-income country in sub-Saharan Africa with limited health care infrastructure and high prevalance of HIV and tuberculosis. This study aims to determine the characteristics of patients presenting to Queen Elizabeth Central Hospital Oncology Unit, Blantyre, Malawi, who had been treated for tuberculosis before they were diagnosed with cancer.Clinical data on all patients (...) presenting to the oncology unit at Queen Elizabeth Central Hospital from 2010 to 2014 after a prior diagnosis of tuberculosis were prospectively recorded, and a descriptive analysis was undertaken.Thirty-four patients who had been treated for tuberculosis before being diagnosed with cancer were identified between 2010 and 2014, which represents approximately 1% of new referrals to the oncology unit. Forty-one percent of patients were HIV positive. Mean duration of tuberculosis treatment before

2016 Journal of global oncology

167. Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana Full Text available with Trip Pro

Collision of Three Pandemics: The Coexistence of Cervical Cancer, HIV Infection, and Prior Tuberculosis in the Sub-Saharan Country of Botswana Cervical cancer is the leading cause of cancer-related mortality in the developing world, where HIV and Mycobacterium tuberculosis (TB) infection are also endemic. HIV infection is independently associated with increased morbidity and mortality among women with cervical cancer. TB is believed to increase the risk of malignancies and could cause chronic

2016 Journal of global oncology

168. Clinical Practice Guidelines on Prevention, Diagnosis and Management of Tuberculosis

Clinical Practice Guidelines on Prevention, Diagnosis and Management of Tuberculosis Academy of Medicine Singapore College of Family Physicians, Singapore Singapore Medical Association Chapter of Infectious Disease Physicians College of Physicians, Singapore Chapter of Respiratory Physicians College of Physicians, Singapore MOH Clinical Practice Guidelines 1/2016 Mar 2016 MINISTRY OF HEALTH SINGAPORE Prevention, Diagnosis and Management of Tuberculosis ISBN 978-981-09-8528-8 Ministry of Health (...) development group. Inside Back CoverA Prevention, Diagnosis and Management of Tuberculosis CLINICAL PRACTICE GUIDELINES MOH Clinical Practice Guidelines 1/2016 B Published by Ministry of Health, Singapore 16 College Road, College of Medicine Building Singapore 169854 Printed by Kwok Printers Pte Ltd Copyright © 2016 by Ministry of Health, Singapore ISBN 978-981-09-8528-8 Available on the MOH website: http://www.moh.gov.sg/cpg These guidelines are not intended to serve as a standard of medical care

2016 Ministry of Health, Singapore

169. BTS Clinical Statement on the Management of Multidrug-Resistant Tuberculosis (MDRTB)

BTS Clinical Statement on the Management of Multidrug-Resistant Tuberculosis (MDRTB) CLINICAL ST A TEMENT November 2016 THE MANAGEMENT OF MUL TIDRUG-RESIST ANT TUBERCULOSIS (MDRTB) CONTEXT The World Health Organization (WHO) has recently updated its guidance on the management of MDRTB (June 2016). Worldwide, there were an estimated 480,000 cases of MDRTB in 2014, the highest rates being in those from Eastern Europe and the Central Asian republics. In the same year , there were 52 notified cases (...) in England (1.4% of all TB); treatment was completed within 24 months in just 54% cases. The management of MDRTB is more complex and associated with more adverse effects than standard treatment. Prior to effective chemotherapy, about a third of patients with tuberculosis remained alive but with a persistently positive sputum smear , i.e. they remained infectious. Failure to control MDRTB will have significant risks to public health. Shorter regimens are preferred by patients and are cheaper . Preliminary

2016 British Thoracic Society

170. Public health guidance on tuberculosis control in vulnerable and hard-to-reach populations

Public health guidance on tuberculosis control in vulnerable and hard-to-reach populations SCIENTIFIC ADVICE www.ecdc.europa.eu Guidance on tuberculosis control in vulnerable and hard-to-reach populations ECDC SCIENTIFIC ADVICE Guidance on tuberculosis control in vulnerable and hard-to-reach populations ii This guidance was coordinated by the ECDC project manager Andreas Sandgren, and produced by an ECDC editorial team consisting of Andreas Sandgren, Marieke J. van der Werf, Netta Beer (...) and the ad hoc scientific panel. In the process of developing this guidance document, four systematic reviews on interventions for tuberculosis identification and management in hard-to-reach and vulnerable populations were performed under service contract No. ECD.5078 (OJ/02/05/2014-PROC/2014/014), by the Academic Medical Centre, University of Amsterdam. We would like to acknowledge the work performed under the contract by Charlotte C. Heuvelings, Sophia G. de Vries, Patrick F. Greve, Benjamin J. Visser

2016 European Centre for Disease Prevention and Control - Public Health Guidance

171. Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines

Treatment of Drug-Susceptible Tuberculosis: Official ATS/CDC/IDSA Clinical Practice Guidelines Clinical Infectious Diseases IDSA GUIDELINE Of?cial American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis Payam Nahid, 1 Susan E. Dorman, 2 Narges Alipanah, 1 Pennan M. Barry, 3 Jan L. Brozek, 4 Adithya Cattamanchi, 1 Lelia H. Chaisson, 1 Richard E. Chaisson, 2 Charles L (...) of Public Health, Richmond; 4 McMaster University, Hamilton, Ontario, Canada; 5 National Jewish Health, Denver, Colorado; 6 World Health Organization, Geneva, Switzerland; 7 Tuberculosis Control Section, San Francisco Department of Public Health, California; 8 Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; 9 Harvard Medical School, Boston, Massachusetts; 10 McGill University

2016 American Thoracic Society

172. Diagnosis of Tuberculosis in Adults and Children

Diagnosis of Tuberculosis in Adults and Children Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America

173. Treatment of Drug-Susceptible Tuberculosis

Treatment of Drug-Susceptible Tuberculosis Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process, review of evidence, and documentation. [Institute

2016 Infectious Diseases Society of America

174. Imaging of Possible Tuberculosis

Imaging of Possible Tuberculosis American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material is permitted for research, scientific and/or information purposes only. You may not modify (...) or create derivative works based on American College of Radiology material. No part of any material posted on the American College of Radiology Web site may be copied, downloaded, stored in a retrieval system, or redistributed for any other purpose without the expressed written permission of American College of Radiology. New 2016 ACR Appropriateness Criteria ® 1 Imaging of Possible Tuberculosis American College of Radiology ACR Appropriateness Criteria ® Imaging of Possible Tuberculosis Variant 1

2016 American College of Radiology

176. Latent Tuberculosis Infection: Screening

Latent Tuberculosis Infection: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Asymptomatic adults at increased risk for infection The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk. B View the Clinical Summary in Population Asymptomatic adults at increased risk for infection Recommendation Screen for latent tuberculosis infection (LTBI). Grade: B Risk (...) Assessment Populations at increased risk for LTBI include persons who were born in, or are former residents of, countries with increased tuberculosis prevalence and persons who live in, or have lived in, high-risk congregate settings (eg, homeless shelters and correctional facilities). Local demographic patterns may vary across the United States; clinicians can consult their local or state health departments for more information about populations at risk in their community. Screening Tests Screening

2016 U.S. Preventive Services Task Force

177. Primary tuberculosis of palate Full Text available with Trip Pro

Primary tuberculosis of palate Primary tuberculosis (TB) of the hard palate is very rare. A 74-year-old man was presented with 6-month history of dysphagia along with an irregular mass in the hard and soft palate. Magnetic resonance imaging (MRI) revealed thickened and increased signal intensity within hard and soft palate. Tissue biopsy showed focal caseating granulomatous-like lesion and the histochemical staining using Ziehl-Neelsen stain for acid-fast bacilli was positive. Positive

2015 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

178. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. Full Text available with Trip Pro

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. 26649984 2015 12 18 2015 12 17 1533-4406 373 25 2015 Dec 17 The New England journal of medicine N. Engl. J. Med. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. e29 10.1056/NEJMx150041 eng Published Erratum 2015 12 09 United States N Engl J Med 0255562 0028-4793 N Engl J Med. 2015 Nov 12;373(20):1986-8 26559594 Stuckia, David [corrected to Stucki, David] 2015 12 10 6 0 2015 12 10 6 0 2015

2015 NEJM

179. Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora Full Text available with Trip Pro

Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora There is an urgent need to discover and develop new drugs to combat Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) in humans. In recent years, there has been a renewed interest in the discovery of new anti-TB agents from natural sources. In the present investigation, molecular docking studies were carried out (...) on two ellagic acid derivatives, namely pteleoellagic acid (1) isolated from Ludwigia adscendens, and 3,3'-di-O-methyl ellagic acid 4-O-α-rhamnopyranoside (2) isolated from Trewia nudiflora, to investigate their binding to two enzymes involved in M. tuberculosis cell wall biogenesis, namely 2-trans-enoyl-ACP reductase (InhA) and β-ketoacyl-ACP reductase (MabA), and to pantothenate kinase (PanK type I) involved in the biosynthesis of coenzyme A, essential for the growth of M. tuberculosis.Molecular

2015 In silico pharmacology

180. Disseminated Tuberculosis in an Immunocompetent Patient: The Answer is in the Liver Full Text available with Trip Pro

Disseminated Tuberculosis in an Immunocompetent Patient: The Answer is in the Liver Tuberculosis, a chronic infectious disease caused by Mycobacterium tuberculosis, may invade all organs but mainly affect the lungs. We report a case of disseminated tuberculosis with hepatic, pericardial and pleural involvement and a review of the relevant literature. A 64-year-old Portuguese male was admitted with epigastric and right upper quadrant pain associated with low grade fever, fatigue, nausea (...) , anorexia, weight loss (6 kg) and mild jaundice. A chest X-ray showed cardiomegaly and a computed tomographic scan of the thorax and abdomen revealed a mild left pleural effusion, a thickened pericardium with signs of incipient calcification and hepatomegaly. The echocardiogram suggested the diagnosis of constrictive pericarditis. Liver biopsy revealed granulomatous lesions with central caseating necrosis. Tuberculosis is usually associated with atypical clinical manifestations. Imaging examination

2015 GE Portuguese journal of gastroenterology